Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice

Inês Sousa-Lima, Shin Young Park, Michelle Chung, Hyun Ju Jung, Min Cheol Kang, Joana M. Gaspar, Ji A Seo, M. Paula Macedo, Kyong Soo Park, Christos Mantzoros, Seung Hoon Lee, Young Bum Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Methylsulfonylmethane (MSM), an organosulfur compound, has been used as a dietary supplement that can improve various metabolic diseases. However, the effect of MSM on obesity-linked metabolic disorders remains unclear. The goal of the current study is to determine whether MSM has beneficial effects on glucose and lipid homeostasis in obesity-associated pathophysiologic states. High-fat diet-induced obese (DIO) and genetically obese diabetic db/db mice treated with MSM (1%–5% v/v, by drinking water) were studied. Metabolic parameters involved in glucose and lipid metabolism were determined. Treatment of DIO mice with MSM leads to a significant decrease in blood glucose levels. DIO mice treated with MSM are hypersensitive to insulin, as evidenced by decreased serum insulin and an increase in the area above the curve during an ITT. Concurrently, MSM reduces hepatic triglyceride and cholesterol contents in DIO mice. These effects are accompanied by reductions in gene expression of key molecules involved in lipogenesis and inflammation. FACS analysis reveals that MSM markedly increases the frequency of B cells and decreases the frequency of myeloid cells in peripheral blood and in bone marrow. Moreover, overnutrition-induced changes of femur microarchitecture are restored by MSM. In db/db mice, a marked impairment in glucose and lipid metabolic profiles is notably ameliorated when MSM is supplemented. These data suggest that MSM has beneficial effects on multiple metabolic dysfunctions, including hyperglycemia, hyperinsulinemia, insulin resistance, and inflammation. Thus, MSM could be the therapeutic option for the treatment of obesity-related metabolic disorders such as type 2 diabetes and fatty liver diseases.

Original languageEnglish
Pages (from-to)26-495
Number of pages470
JournalMetabolism: Clinical and Experimental
Volume65
Issue number10
DOIs
Publication statusPublished - 2016 Oct 1
Externally publishedYes

Fingerprint

Obesity
Obese Mice
Diet
Glucose
dimethyl sulfone
Overnutrition
Insulin
Inflammation
Lipids
Lipogenesis
Metabolome
Metabolic Diseases
Hyperinsulinism
High Fat Diet
Myeloid Cells
Fatty Liver
Dietary Supplements
Lipid Metabolism
Drinking Water
Hyperglycemia

Keywords

  • Hepatic steatosis
  • Inflammation
  • Methylsulfonylmethane
  • Obesity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice. / Sousa-Lima, Inês; Park, Shin Young; Chung, Michelle; Jung, Hyun Ju; Kang, Min Cheol; Gaspar, Joana M.; Seo, Ji A; Macedo, M. Paula; Park, Kyong Soo; Mantzoros, Christos; Lee, Seung Hoon; Kim, Young Bum.

In: Metabolism: Clinical and Experimental, Vol. 65, No. 10, 01.10.2016, p. 26-495.

Research output: Contribution to journalArticle

Sousa-Lima, I, Park, SY, Chung, M, Jung, HJ, Kang, MC, Gaspar, JM, Seo, JA, Macedo, MP, Park, KS, Mantzoros, C, Lee, SH & Kim, YB 2016, 'Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice', Metabolism: Clinical and Experimental, vol. 65, no. 10, pp. 26-495. https://doi.org/10.1016/j.metabol.2016.07.007
Sousa-Lima, Inês ; Park, Shin Young ; Chung, Michelle ; Jung, Hyun Ju ; Kang, Min Cheol ; Gaspar, Joana M. ; Seo, Ji A ; Macedo, M. Paula ; Park, Kyong Soo ; Mantzoros, Christos ; Lee, Seung Hoon ; Kim, Young Bum. / Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice. In: Metabolism: Clinical and Experimental. 2016 ; Vol. 65, No. 10. pp. 26-495.
@article{029b2fcabf6d4d2baf4c40f21c8109bd,
title = "Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice",
abstract = "Methylsulfonylmethane (MSM), an organosulfur compound, has been used as a dietary supplement that can improve various metabolic diseases. However, the effect of MSM on obesity-linked metabolic disorders remains unclear. The goal of the current study is to determine whether MSM has beneficial effects on glucose and lipid homeostasis in obesity-associated pathophysiologic states. High-fat diet-induced obese (DIO) and genetically obese diabetic db/db mice treated with MSM (1{\%}–5{\%} v/v, by drinking water) were studied. Metabolic parameters involved in glucose and lipid metabolism were determined. Treatment of DIO mice with MSM leads to a significant decrease in blood glucose levels. DIO mice treated with MSM are hypersensitive to insulin, as evidenced by decreased serum insulin and an increase in the area above the curve during an ITT. Concurrently, MSM reduces hepatic triglyceride and cholesterol contents in DIO mice. These effects are accompanied by reductions in gene expression of key molecules involved in lipogenesis and inflammation. FACS analysis reveals that MSM markedly increases the frequency of B cells and decreases the frequency of myeloid cells in peripheral blood and in bone marrow. Moreover, overnutrition-induced changes of femur microarchitecture are restored by MSM. In db/db mice, a marked impairment in glucose and lipid metabolic profiles is notably ameliorated when MSM is supplemented. These data suggest that MSM has beneficial effects on multiple metabolic dysfunctions, including hyperglycemia, hyperinsulinemia, insulin resistance, and inflammation. Thus, MSM could be the therapeutic option for the treatment of obesity-related metabolic disorders such as type 2 diabetes and fatty liver diseases.",
keywords = "Hepatic steatosis, Inflammation, Methylsulfonylmethane, Obesity, Type 2 diabetes",
author = "In{\^e}s Sousa-Lima and Park, {Shin Young} and Michelle Chung and Jung, {Hyun Ju} and Kang, {Min Cheol} and Gaspar, {Joana M.} and Seo, {Ji A} and Macedo, {M. Paula} and Park, {Kyong Soo} and Christos Mantzoros and Lee, {Seung Hoon} and Kim, {Young Bum}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.metabol.2016.07.007",
language = "English",
volume = "65",
pages = "26--495",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Methylsulfonylmethane (MSM), an organosulfur compound, is effective against obesity-induced metabolic disorders in mice

AU - Sousa-Lima, Inês

AU - Park, Shin Young

AU - Chung, Michelle

AU - Jung, Hyun Ju

AU - Kang, Min Cheol

AU - Gaspar, Joana M.

AU - Seo, Ji A

AU - Macedo, M. Paula

AU - Park, Kyong Soo

AU - Mantzoros, Christos

AU - Lee, Seung Hoon

AU - Kim, Young Bum

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Methylsulfonylmethane (MSM), an organosulfur compound, has been used as a dietary supplement that can improve various metabolic diseases. However, the effect of MSM on obesity-linked metabolic disorders remains unclear. The goal of the current study is to determine whether MSM has beneficial effects on glucose and lipid homeostasis in obesity-associated pathophysiologic states. High-fat diet-induced obese (DIO) and genetically obese diabetic db/db mice treated with MSM (1%–5% v/v, by drinking water) were studied. Metabolic parameters involved in glucose and lipid metabolism were determined. Treatment of DIO mice with MSM leads to a significant decrease in blood glucose levels. DIO mice treated with MSM are hypersensitive to insulin, as evidenced by decreased serum insulin and an increase in the area above the curve during an ITT. Concurrently, MSM reduces hepatic triglyceride and cholesterol contents in DIO mice. These effects are accompanied by reductions in gene expression of key molecules involved in lipogenesis and inflammation. FACS analysis reveals that MSM markedly increases the frequency of B cells and decreases the frequency of myeloid cells in peripheral blood and in bone marrow. Moreover, overnutrition-induced changes of femur microarchitecture are restored by MSM. In db/db mice, a marked impairment in glucose and lipid metabolic profiles is notably ameliorated when MSM is supplemented. These data suggest that MSM has beneficial effects on multiple metabolic dysfunctions, including hyperglycemia, hyperinsulinemia, insulin resistance, and inflammation. Thus, MSM could be the therapeutic option for the treatment of obesity-related metabolic disorders such as type 2 diabetes and fatty liver diseases.

AB - Methylsulfonylmethane (MSM), an organosulfur compound, has been used as a dietary supplement that can improve various metabolic diseases. However, the effect of MSM on obesity-linked metabolic disorders remains unclear. The goal of the current study is to determine whether MSM has beneficial effects on glucose and lipid homeostasis in obesity-associated pathophysiologic states. High-fat diet-induced obese (DIO) and genetically obese diabetic db/db mice treated with MSM (1%–5% v/v, by drinking water) were studied. Metabolic parameters involved in glucose and lipid metabolism were determined. Treatment of DIO mice with MSM leads to a significant decrease in blood glucose levels. DIO mice treated with MSM are hypersensitive to insulin, as evidenced by decreased serum insulin and an increase in the area above the curve during an ITT. Concurrently, MSM reduces hepatic triglyceride and cholesterol contents in DIO mice. These effects are accompanied by reductions in gene expression of key molecules involved in lipogenesis and inflammation. FACS analysis reveals that MSM markedly increases the frequency of B cells and decreases the frequency of myeloid cells in peripheral blood and in bone marrow. Moreover, overnutrition-induced changes of femur microarchitecture are restored by MSM. In db/db mice, a marked impairment in glucose and lipid metabolic profiles is notably ameliorated when MSM is supplemented. These data suggest that MSM has beneficial effects on multiple metabolic dysfunctions, including hyperglycemia, hyperinsulinemia, insulin resistance, and inflammation. Thus, MSM could be the therapeutic option for the treatment of obesity-related metabolic disorders such as type 2 diabetes and fatty liver diseases.

KW - Hepatic steatosis

KW - Inflammation

KW - Methylsulfonylmethane

KW - Obesity

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84980329397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980329397&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2016.07.007

DO - 10.1016/j.metabol.2016.07.007

M3 - Article

C2 - 27621186

AN - SCOPUS:84980329397

VL - 65

SP - 26

EP - 495

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 10

ER -